NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
IPO Year:
Exchange: NASDAQ
Website: neubasetherapeutics.com
HC Wainwright & Co. reiterated coverage of NeuBase Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously
HC Wainwright & Co. reiterated coverage of NeuBase Therapeutics with a rating of Buy and set a new price target of $18.00 from $15.00 previously
8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)
DEFA14A - NeuBase Therapeutics, Inc. (0001173281) (Filer)
8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)
DEFA14A - NeuBase Therapeutics, Inc. (0001173281) (Filer)
8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)
DEF 14A - NeuBase Therapeutics, Inc. (0001173281) (Filer)
8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)
PRE 14A - NeuBase Therapeutics, Inc. (0001173281) (Filer)
8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)
8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)